Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

completed133%
active_not_recruiting133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingphase_3

R21/Matrix-M in African Children Against Clinical Malaria

NCT04704830
completedphase_1

Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

NCT05385510
terminatedphase_2

A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults

NCT03947190

Clinical Trials (3)

Showing 3 of 3 trials
NCT04704830Phase 3

R21/Matrix-M in African Children Against Clinical Malaria

Active Not Recruiting
NCT05385510Phase 1

Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

Completed
NCT03947190Phase 2

A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults

Terminated

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3